FDA's Prasad ex­plains ra­tio­nale be­hind paus­ing Val­neva's chikun­gun­ya vac­cine in se­niors

The FDA and CDC’s de­ci­sion last month to pause ad­min­is­ter­ing Val­ne­va’s live-at­ten­u­at­ed chikun­gun­ya vac­cine in pa­tients 60 and old­er was meant to pro­vide more time …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER